Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.30
-0.14 (-0.68%)
At close: Jul 3, 2025, 1:00 PM
20.50
+0.20 (0.99%)
After-hours: Jul 3, 2025, 4:28 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Reimbursement | 138.35M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Reimbursement Growth | -1.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Milestone | 138.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Milestone Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
License | 277.81K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 242.11M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 158.67% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
DARZALEX Royalties | 1.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
DARZALEX Royalties Growth | 23.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Kesimpta Royalties | 308.65M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Kesimpta Royalties Growth | 42.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
TEPEZZA Royalties | 102.37M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
TEPEZZA Royalties Growth | 0.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Royalties | 65.42M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Royalties Growth | 75.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Collaboration | 60.15M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Collaboration Growth | 32.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Net Product Sales | 242.11M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Net Product Sales Growth | 157.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
J&J | 2.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
J&J Growth | 22.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Novartis | 391.99M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Novartis Growth | 75.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BioNTech | 120.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
BioNTech Growth | -7.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pfizer | 74.04M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pfizer Growth | 34.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Collaboration Partner | 277.81K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Collaboration Partner Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Roche | 102.93M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Roche Growth | 1.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
AbbVie | 54.73M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
AbbVie Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Denmark | 2.75B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Denmark Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 125.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Japan | 116.82M |
Log In |
Log In |
Log In |
Log In | Upgrade
|